Showing results (851-860 of 996) with videos related to

Sort By:
Pageof 100
Breast Cancer Research and Treatment|June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancerYifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Cancer Immunology, Immunotherapy : CII|June 8, 2024
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinomaDomenico Mallardo, Francesca Sparano, Maria Grazia Vitale, et al.
Andrology|April 6, 2026
Living Together, Loving Apart: Health, Sexuality and Relationships in Middle-Aged and Older Men in EuropeClotilde Sparano, Giammarco Alderotti, Giulia Rastrelli, et al.
International Journal of Psychology : Journal International De Psychologie|July 28, 2015
Longitudinal trajectories of bicultural identity integration in recently immigrated Hispanic adolescents: Links with mental health and family functioningSeth J Schwartz, Jennifer B Unger, Lourdes Baezconde-Garbanati, et al.
Breast Cancer Research and Treatment|June 25, 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancerMatthew Kearney, Lauren Franks, Shing Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2008
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic featuresLori J Goldstein, Robert Gray, Sunil Badve, et al.
Frontiers in Oncology|July 3, 2020
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast CancerDouglas K Marks, Robyn D Gartrell, Margueritta El Asmar, et al.
Breast Cancer Research and Treatment|February 2, 2018
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studiesE Rakovitch, R Gray, F L Baehner, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerJoseph A Sparano, Stacy Moulder, Aslamuzzaman Kazi, et al.
Pageof 100